Kristen Yen - Aug 26, 2022 Form 4 Insider Report for SOLENO THERAPEUTICS INC (SLNO)

Role
Officer title: Vice President, Clinical Operations
Signature
/s/ Anish Bhatnagar, Attorney-in-Fact
Stock symbol
SLNO
Transactions as of
Aug 26, 2022
Transactions value $
$0
Form type
4
Date filed
10/14/2022, 06:54 PM
Previous filing
Jul 29, 2022
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding SLNO Common Stock 4.43K Aug 26, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SLNO Employee stock option (right to buy) 698 Aug 26, 2022 Common Stock 698 $535.50 Direct F3, F4
holding SLNO Employee stock option (right to buy) 133 Aug 26, 2022 Common Stock 133 $135.00 Direct F3, F4
holding SLNO Employee stock option (right to buy) 174 Aug 26, 2022 Common Stock 174 $135.00 Direct F3, F4
holding SLNO Employee stock option (right to buy) 666 Aug 26, 2022 Common Stock 666 $120.75 Direct F3, F4
holding SLNO Employee stock option (right to buy) 488 Aug 26, 2022 Common Stock 488 $90.00 Direct F3, F4
holding SLNO Employee stock option (right to buy) 1.74K Aug 26, 2022 Common Stock 1.74K $44.25 Direct F3, F4
holding SLNO Employee stock option (right to buy) 5K Aug 26, 2022 Common Stock 5K $24.00 Direct F4, F5
holding SLNO Employee stock option (right to buy) 4K Aug 26, 2022 Common Stock 4K $25.05 Direct F5, F6
holding SLNO Employee stock option (right to buy) 666 Aug 26, 2022 Common Stock 666 $51.15 Direct F5, F7
holding SLNO Employee stock option (right to buy) 18.8K Aug 26, 2022 Common Stock 18.8K $33.60 Direct F5, F8
holding SLNO Employee stock option (right to buy) 7.33K Aug 26, 2022 Common Stock 7.33K $5.10 Direct F5, F9
holding SLNO Employee stock option (right to buy) 13.3K Aug 26, 2022 Common Stock 13.3K $2.60 Direct F5, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022.
F2 Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
F3 The per share exercise price and number of shares subject to the option reflect the 1-for-5 reverse stock split effected October 15, 2017 and the 1-for-15 reverse stock split effected August 26, 2022.
F4 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
F5 The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022.
F6 One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of January 24, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F7 One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of May 18, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F8 Twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option shall vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F9 One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date"), and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date.
F10 One fourth of the shares subject to the option shall vest on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.

Remarks:

Officer title: Vice President, Clinical Operations